Market Analysis - Dual Diagnosis Disorders 2018
Summary of Dual Diagnosis Disorders 2018:
Dual diagnosis is when a person is affected by both mental illness and substance use also referred to as the use of alcohol and/or drugs. Dual diagnosis is a term typically used to refer to individuals who are living with a mental illness and substance abuse issue at the same time, and as a result are suffering from co-morbidity or co-occurring disorder (COD).
Recovery from mental illness is much more challenging for people with a dual diagnosis, and the issues faced by families of people with dual diagnosis can be more complex and confusing than mental illness alone. Research has recently determined that people with mental illness use drugs and alcohol for the same reason as other people to feel better or different, relax, have fun and be part of a group.
Market analysis around the globe:
The global market for drugs used in mental disorders was $70.1 billion in 2012 and $68.9 billion in 2013. This market is expected to rise at a compound annual growth rate (CAGR) of 2.3% from 2013 to 2018 and reach $77.1 billion by 2018.
Market analysis around Australia:
It is estimated that 436,000 people, or 49% of all those with a mental or substance use disorder, received treatment in Australia in 2011-12. Approximately 74,000 people (17%) were estimated to be treated by public specialised services. Of the remainder, a further 178,000 people (41%) were receiving Medicare subsidised treatment from psychiatrists and allied health professionals and another 134,000 people (31%) received mental health care from a GP only. Small numbers of people were treated by other health services (37,000, or 8%) or under the DVA health service structure (13,000, or 3%). Indicative data suggest that treatment coverage varied considerably according to severity of disorder (94% for people with severe disorders, 64% for people with moderate disorders, and 26% for those with mild disorder), Community prevalence and treatment rates for mental and substance use disorders 2 Five year trends in treatment data show that treatment rates have been increasing over time, with most of this growth occurring in Commonwealth funded general practitioner, psychiatrist and allied health professional mental health services.
The scope of this study encompasses psychiatric drugs in pharmaceutical markets. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes countries like India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand, etc.
Scope and importance:
The subject of Dual Diagnosis is of primary concern to counsellors and treatment professionals in both mental health and substance abuse facilities. Many counsellors and treatment professionals are specialists in either substance abuse or mental health and are ignorant or intimidated by co-existing mental health problems (Daley, Moss, and Campbell, 1987, Hatfield, 1993, and O’Connell, 1990).
All treatment professionals, physicians, mental health professionals, addiction/recovery professionals, and lay counsellor’s are presented with problems outside of their scope of practice. Recognition of these problems, referral to appropriate treatment professionals and collaboration with these professionals is important in providing appropriate treatment to the individual patient/client.
Why in Melbourne, Australia:
Australian researchers planned and conducted the Australian National Survey of Mental Health and Wellbeing (NSMHWB) in 1997. It involved a modified version of the CIDI (which is a more recent version of the DIS) and used DSM-IV criteria. The nationally representative NSMHWB sample involved the assessment of ICD-10 and DSM-IV substance use disorders, mood disorders, anxiety disorders, and it also screened for likely cases of psychosis (Hall, Teesson, Lynskey, & Degenhardt, 1999; Henderson, Andrews, & Hall, 2000).
In recent decades, psychiatric services have been challenged to be more responsive to patients’ coexisting problems, in particular those concerning substance use. In Australia this has been referred to as a “No Wrong Door” approach. the acute mental health sector, including attitudes toward a No Wrong Door approach to people with a dual diagnosis of mental illness and substance use disorder. Patients at the Thomas Embling Hospital in Victoria, Australia, were assessed to determine the prevalence of substance abuse disorders and mental illnesses within this population. Results reveal that the majority of patients (approximately 74%) have a lifetime substance abuse or dependence disorder. Information was collected concerning patients' criminal histories and the Level of Service Inventory, Revised, was completed for each patient who participated. Results suggest that patients with both major mental illnesses and substance abuse disorders have more extensive criminal histories and demonstrate a higher level of risks and needs when compared with patients with major mental illness alone.
Why Melbourne, Australia in November
Springtime visitors will enjoy blooming flowers and rising temps that range from the high 40s to the low 70s. Plus, travellers don't have to elbow their way through crowds at The Block Arcade or the National Gallery of Victoria because the city has yet to see the winter tourist torrent. Melbourne’s weather results from the eastward flow of high-pressure cells separated by low-pressure troughs. These patterns follow a course that passes south of the continent in summer and over northern Victoria in winter.
Substance use disorders
Epidemiology and Dual Disorders
Psychosis & Schizophrenia
Addiction & Neurotoxicology
Depression & Anxiety
Borderline Personality Disorder
Pharmacology : Dual Disorders
Behavioral Addictions and Dual Disorders
Dual Diagnosis and Recovery
Dual Disorders in Geriatrics
Dual Diagnosis : Nursing
Clinical Interventions & Case Reports